The company said it expects full-year 2025 revenue in the range of $61.0 billion to $64.0 billion. It said this represents operational growth of roughly flat to 5% from the midpoint of the 2024 baseline guidance.

1. 01

   The company said it expects full-year 2025 revenue in the range of $61.0 billion to $64.0 billion. It said this represents operational growth of roughly flat to 5% from the midpoint of the 2024 baseline guidance.

2. 02

   Pfizer said it expects full-year 2025 adjusted diluted EPS in the range of $2.80 to $3.00. It said this represents operational growth of 10% to 18% from the midpoint of the 2024 baseline guidance range of $2.45 to $2.65.

3. 03

   The company said non-recurring items in 2025 will not recur in 2024 and are expected to favorably impact adjusted diluted EPS by approximately $0.30. It cited Paxlovid revenue of $1.2 billion (including $771 million from a U.S. government true-up and $442 million from stockpile delivery), Haleon equity method income, and tax rate effects as factors.

4. 04

   Pfizer expects full-year 2025 adjusted SI&A expenses of $13.3 to $14.3 billion and adjusted R&D expenses of $10.7 to $11.7 billion. The company said it achieved approximately $4.0 billion in net operating expense savings through the end of 2024 and expects an additional $500 million in savings in 2025.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.